This CPB is revised to state that bendamustine (Bendeka, Treanda) for the following diseases is considered medically necessary for the following indications: 1) Adult T-cell leukemia/lymphoma - for nonresponders to first-line therapy; 2) AIDS-related B-cell lymphoma (AIDS-related diffuse large B-cell lymphoma, primary effusion lymphoma, and lymphoma associated with Castleman's disease ) - second-line or subsequent therapy; 3) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) -  as a single agent or in combination with rituximab; 4) Classical Hodgkin's lymphoma - use as a single agent for relapsed or refractory disease in adults (> 18) or palliative therapy in older adults (> 60); 5) Diffuse large B-cell lymphoma - second-line or subsequent therapy with or without rituximab for relapsed or refractory disease; 6) Follicular lymphoma - as a single agent or in combination with rituximab; 7) Gastric MALT lymphoma - as a single agent or in combination with rituximab; 8) Mantle cell lymphoma - as a single agent or in combination with rituximab; 10 Multiple myeloma - relapsed or progressive or refractory disease; 11) Mycosis fungoides - single agent therapy; 12) Non-gastric MALT lymphoma - as a single agent or in combination with rituximab; 13) Peripheral T-cell lymphoma (relapsed or refractory angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified, anaplastic large cell lymphoma, or enteropathy-associated T-cell lymphoma) - second-line or subsequent therapy for relapsed or refractory disease; 14) Primary cutaneous CD30+ T-cell lymphoproliferative disorders - single-agent therapy for relapsed or refractory disease; 15) Primary cutaneous B-cell lymphoma (primary cutaneous marginal zone, follicle center lymphoma, and leg-type primary cutaneous diffuse large B-cell lymphoma)  - used in combination with rituximab; 16) Sezary syndrome - single agent therapy; 17) Small cell lung cancer - subsequent chemotherapy for relapsed or progressive disease; 18) Splenic marginal zone lymphoma - as a single agent or in combination with rituximab; and 19) Waldenstrom's macroglobulinemia/Lymphoplasmacytic lymphoma - as a single agent or in combination with rituximab. This CPB is revised to state that bendamustine is considered not medically necessary if there is disease progression constituting treatment failure on bendamustine. The title of this CPB has been changed to "Bendamustine (Bendeka and Treanda)."